Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Average Rating of "Hold" by Analysts
Six research firms have given Akebia Therapeutics (NASDAQ:AKBA) an average rating of "Hold", with a consensus 12-month target price of $3.75. Recent analyst reports show mixed sentiment, including upgrades, downgrades, and reiterations of "buy" and "sell" ratings. The company recently reported better-than-expected earnings and revenue for the last quarter.
Piper Sandler Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $4
Piper Sandler has reiterated its Buy rating on Akebia Therapeutics (AKBA.US) and maintained its target price at $4. This indicates continued confidence from the analyst firm in the company's prospects.
Akebia Therapeutics, Inc. $AKBA Shares Sold by Renaissance Technologies LLC
Renaissance Technologies LLC significantly reduced its stake in Akebia Therapeutics (NASDAQ:AKBA) during the first quarter, selling 1.76 million shares and retaining 1.83 million, now valued at $2.55 million. Despite this, Akebia reported stronger-than-expected quarterly revenues of $49.13 million and a smaller loss per share of $0.02, surpassing analyst estimates. The stock, currently trading near its 52-week low, holds an average "Hold" rating from analysts with a consensus price target of $3.75, while institutional investors collectively own 33.92% of the company.
HC Wainwright Has Negative Outlook of AKBA FY2026 Earnings
HC Wainwright has revised its FY2026 earnings estimate for Akebia Therapeutics (NASDAQ:AKBA) to a loss of $0.12 per share, down from a previous estimate of $0.08, while maintaining a "Buy" rating. Despite this negative revision, Akebia recently exceeded expectations in its latest quarterly results, reporting a $0.02-per-share loss against a projected $0.04 loss and higher-than-expected revenue. The stock currently holds a consensus "Hold" rating with a target price of $3.75, trading near its 52-week low.
Akebia Therapeutics (AKBA) AGM 2026 Summary
This article summarizes Akebia Therapeutics' (AKBA) 2026 Annual General Meeting (AGM), detailing the agenda, including the election of Class III directors, approval of an increase in authorized capital, an advisory vote on executive compensation, and the ratification of Ernst & Young LLP as the independent auditor. It also outlines the voting outcomes, confirming the election of directors, approval of share authorization, passing of executive compensation, and ratification of the auditor. The summary also includes a list of recent company events and their financial highlights.
Akebia Therapeutics (NASDAQ:AKBA) Downgraded by Leerink Partners to "Market Perform"
Leerink Partners has downgraded Akebia Therapeutics (NASDAQ:AKBA) from "Outperform" to "Market Perform," setting a new price target of $1.00. This downgrade implies a potential upside of 4.78% from its previous close. Despite beating quarterly EPS and revenue estimates, Akebia's shares fell 26%, opening at $0.95, indicating mixed analyst sentiment with a consensus "Hold" rating and an average target price of $3.75.
Akebia Therapeutics (AKBA) Stock Price Sinks As Losses Deepen Value Doubts
Akebia Therapeutics (AKBA) stock fell 26% to US$0.95 following a Q2 2026 earnings report showing revenue decline and a net loss, raising concerns about its valuation. While the company's Vafseo product is showing strong growth, the overall revenue fall and decline in Auryxia sales, coupled with ongoing funding needs, present a challenging outlook for investors. The market is questioning whether its low price-to-sales ratio reflects a deep value opportunity or simply its persistent losses and dilution risks.
Akebia Therapeutics Q2 Earnings Call Highlights
Akebia Therapeutics reported its second-quarter earnings, highlighting significant revenue growth for its Vafseo anemia treatment and positive interim results from the VOICE study, which met its stopping criteria for non-inferiority and superiority. The company also detailed advancements in its rare kidney disease pipeline with ebribafusp and praliciguat, and provided financial updates, including a net loss of $8.9 million and expectations for Vafseo's pricing post-TDAPA period.
Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases
Akebia Therapeutics has initiated a Phase 2 basket trial to evaluate ebribafusp, a next-generation complement inhibitor, for rare kidney diseases such as IgA nephropathy, lupus nephritis, and C3 glomerulopathy. The trial aims to assess the safety, efficacy, and pharmacokinetics of weekly subcutaneous dosing, focusing on reducing complement activation in the kidney without affecting the blood complement system. Initial data from the open-label study, involving up to 30 patients, is expected in 2027.
Transcript : Akebia Therapeutics, Inc., Q2 2026 Earnings Call, Aug 05, 2026
This article is a transcript of Akebia Therapeutics, Inc.'s Q2 2026 Earnings Call held on August 5, 2026. The content provides details from the call, including an operator's message, but the full transcript is reserved for subscribers. It also lists recent news and financial performance data for Akebia Therapeutics (AKBA).
Akebia Therapeutics Q2 Earnings Call Highlights
Akebia Therapeutics (NASDAQ: AKBA) reported its Q2 2026 earnings, highlighting a significant 60% year-over-year increase in Vafseo revenue to $21.3 million, driven by over 10,500 active patients. The company also announced that its VOICE trial for Vafseo met its interim stopping criteria, demonstrating a statistically significant reduction in mortality and hospitalization. Despite these successes, total revenue declined to $49.1 million due to generic competition impacting Auryxia sales, and the company anticipates a potential decline in Vafseo revenue in 2027 due to pricing reductions after its TDAPA period ends.
Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
Akebia Therapeutics announced strong second-quarter 2026 financial results, with Vafseo net product revenues growing to $21.3 million and over 10,500 patients on therapy. The company also highlighted significant advancements in its rare kidney disease pipeline, including the initiation of a Phase 2 trial for ebribafusp and positive interim analysis from the VOICE trial demonstrating improved safety outcomes for Vafseo. Despite a net loss due to decreased Auryxia revenues and increased expenses, Akebia expects its cash resources and revenues to fund operations for at least two years.
Akebia Therapeutics Inc expected to post a loss of 4 cents a share - Earnings Preview
Akebia Therapeutics Inc is anticipated to report a loss of 4 cents per share. This information comes from a Refinitiv earnings preview. The full article is available through a TradingView subscription.
Two New Akebia Hires Get Stock Options With 4-Year Vesting
Akebia Therapeutics (Nasdaq: AKBA) granted stock options for an aggregate of 61,000 shares to two new employees on July 31, 2026. These inducement awards, granted under Nasdaq Listing Rule 5635(c)(4), have an exercise price of $1.32 per share and will vest over four years, subject to continued employment. This move aims to incentivize and retain key talent within the biopharmaceutical company focused on kidney disease.
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. (Nasdaq: AKBA) reported granting options to purchase 61,000 shares of common stock to two new employees on July 31, 2026. These grants, made as an inducement for employment, comply with Nasdaq Listing Rule 5635(c)(4) and have an exercise price of $1.32 per share. The options vest over four years, with 25% vesting after the first year and the remainder vesting quarterly thereafter, contingent on continued employment.
Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases
Akebia Therapeutics has initiated a Phase 2 basket trial to evaluate ebribafusp, a next-generation complement inhibitor, for rare complement-mediated kidney diseases including IgA nephropathy, lupus nephritis, and C3 glomerulopathy. The trial aims to assess the safety, efficacy, and pharmacokinetics of ebribafusp, which is designed to inhibit complement activation in tissues without affecting the complement system in the blood, potentially offering a safer long-term treatment option. Initial data from the trial, which will enroll up to 30 patients, are expected in 2027.
Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases
Akebia Therapeutics has initiated an open-label Phase 2 basket trial to evaluate ebribafusp, a next-generation complement inhibitor, for rare complement-mediated kidney diseases including IgA nephropathy, lupus nephritis, and C3 glomerulopathy. The trial will assess the safety, efficacy, and pharmacokinetics of weekly subcutaneous dosing of ebribafusp, which is designed to inhibit complement activation in tissues without affecting the complement system in the blood. Initial data from the trial, expected to enroll up to 30 patients, is anticipated in 2027.
Q1 2026 Akebia Therapeutics Inc Earnings Call Transcript
This article provides the transcript for Akebia Therapeutics Inc.'s Q1 2026 earnings call, held on May 7, 2026. The call began with an introduction by an unidentifed speaker, followed by Mercedes Carrasco. The transcript details the proceedings of the financial results conference call, including a question-and-answer session for participants.
Akebia Therapeutics And 2 Promising Penny Stocks To Watch
This article identifies three promising penny stocks for investors to watch: Akebia Therapeutics (AKBA), GoodRx Holdings (GDRX), and Snap (SNAP). It provides a brief financial overview of each company, highlighting their market capitalization, revenue, and key financial challenges or strategic initiatives. While acknowledging the inherent risks of penny stocks, the analysis points to potential growth areas and current financial health ratings for each.
Akebia Therapeutics And 2 Promising Penny Stocks To Watch
This article identifies Akebia Therapeutics (AKBA), GoodRx Holdings (GDRX), and Snap (SNAP) as promising penny stocks to watch, despite challenges like unprofitability and high debt. It provides an overview of each company's financial health, operations, and recent developments. The article emphasizes that while these stocks offer affordability and growth potential, they also come with risks typical of smaller or newer companies.
Akebia Therapeutics And 2 Promising Penny Stocks To Watch
This article identifies Akebia Therapeutics, GoodRx Holdings, and Snap Inc. as promising penny stocks, analyzing their financial health and recent developments. While all three companies face challenges like unprofitability or high debt, they also exhibit growth potential and strategic initiatives. The piece emphasizes that penny stocks offer affordability and growth potential but require careful examination of financials.
Akebia Therapeutics And 2 Promising Penny Stocks To Watch
This article identifies Akebia Therapeutics (AKBA), GoodRx Holdings (GDRX), and Snap (SNAP) as promising penny stocks to watch, despite their current unprofitability and financial challenges. It highlights their market caps, revenues, recent developments, and financial health, noting their potential for growth alongside inherent risks. The analysis emphasizes that these stocks offer a mix of affordability and growth potential when supported by strong financials.
Akebia Therapeutics (AKBA) to Announce Earnings on Thursday
Akebia Therapeutics (AKBA) is scheduled to announce its Q2 2026 earnings before market open on Thursday, August 6th, with analysts expecting a loss of ($0.03) per share and revenue of $48.8520 million. The bi
Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics will announce its second quarter 2026 financial results. The company will also hold a conference call and webcast to discuss these results and provide an update on recent business developments.
Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics, Inc. (Nasdaq: AKBA) announced it will release its second-quarter 2026 financial results on Wednesday, August 5, 2026, after the financial markets close. The company will host a conference call on the same day at 4:30 p.m. EDT to discuss these results and recent business highlights. A live webcast of the call will be available on the Investors section of Akebia’s website.
Akebia Therapeutics, Inc. Revenue Breakdown – BX:AX9
Akebia Therapeutics, Inc. (BX:AX9) generated 187.25 million CHF last year, with its Innovative Therapeutics segment being the top performer. All of this revenue came from the United States market, indicating a focused geographic revenue stream. This represents an increase from 145.48 million CHF the previous year.
Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics announced it will release its second quarter 2026 financial results on Wednesday, August 5, 2026, after market close. The company will also host a conference call on the same day at 4:30 p.m. EDT to discuss these results and recent business highlights. Interested parties can access the call via phone or live webcast.
Akebia plans Aug. 5 webcast after markets close to discuss results
Akebia Therapeutics (Nasdaq: AKBA) will release its second-quarter 2026 financial results on Wednesday, August 5, 2026, after the market closes. The company will host a conference call at 4:30 p.m. EDT on the same day to discuss the results and recent business highlights, accessible by phone or webcast. Historical earnings-date reactions for Akebia have been nonnegative, with an average move of 0.72% in the 24 hours following announcements.
AKBA|Akebia Therapeutics Inc|Price:1.275|Chg%:-0.005
Akebia Therapeutics Inc (AKBA) has a healthy fundamental outlook and high growth potential, with its valuation considered fairly valued. Despite strong analyst ratings with a "Strong Buy" consensus and a high institutional ownership, the stock is currently trading sideways. The company is a biopharmaceutical firm focused on kidney disease treatments, with two commercial products, Auryxia and Vafseo, and has shown steady revenue growth averaging 21.36% year-on-year over the past three years.
Akebia Therapeutics Inc (AKBA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
The article discusses the revenue breakdown of Akebia Therapeutics Inc (AKBA), specifically focusing on its business segments, regional revenue, and profit contribution. However, it explicitly states that the relevant data for these breakdowns have not yet been disclosed by the company.
Akebia Therapeutics Inc (AKBA) Income Statement
This article provides the quarterly and annual income statement for Akebia Therapeutics Inc (AKBA), offering detailed financial data such as total revenue, operating expenses, special income, and net income stretching back to FY2012Q4. It highlights the company's financial performance, including a fiscal year 2025 revenue of $236.20M and net income of -$5.34M. The page also includes FAQs explaining how to interpret income statements and key metrics for analyzing AKBA stock.
Akebia Therapeutics Inc (AKBA) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Akebia Therapeutics Inc's (AKBA) stock performance, market capitalization, and dividend history. It highlights that the company has not distributed any dividends over the past five years. The page also offers general financial data and company information for AKBA.
AKBA|Akebia Therapeutics Inc|Price:1.220|
This article provides a detailed financial summary of Akebia Therapeutics Inc (AKBA), including its income statement, balance sheet, and cash flow statement. It highlights key financial indicators such as EPS, revenue, net profit, net margin, gross margin, and debt-to-asset ratio, especially focusing on quarterly and annual performance up to FY2026Q1. The company's latest earnings released on May 7, 2026, show an EPS of -0.03 and revenue of 53.54M, with analysts rating it a "STRONG BUY."
Akebia Therapeutics Inc (AKBA) Institutional Confidence
Akebia Therapeutics Inc (AKBA) has an institutional shareholding score of 3.00, placing it 92nd out of 155 in the Pharmaceuticals industry. The institutional shareholding proportion increased by 1.21% quarter-over-quarter to 46.96%. James Simons is the largest institutional shareholder, holding 0.68% of outstanding shares, while other major institutions like BlackRock, State Street, and Citadel Advisors have recently increased their holdings.
AKBA|Akebia Therapeutics Inc|Price:1.220|
Akebia Therapeutics Inc (AKBA) is a biopharmaceutical company with two commercial products for kidney disease. The company's fundamentals are healthy, and it demonstrates high growth potential, with revenue growing an average of 21.36% year-on-year over the past three years. Despite institutional selling and lower market activity, analysts rate it as a "Strong Buy" with a target price of $4.20, an upside of 244.26%.
AKBA|Akebia Therapeutics Inc|Price:1.220|
Akebia Therapeutics Inc. (AKBA) is a biopharmaceutical company focused on kidney disease, with commercial products Auryxia and Vafseo. The company's executives and their shareholdings are listed, showing significant positions held by its President and CEO, John P. Butler. As of Q1 2026, 351 institutions hold 46.96% of the total shares, valued at approximately $125.97 million.
Akebia Therapeutics, Inc. Revenue Breakdown – SWB:AX9
Akebia Therapeutics, Inc. (SWB:AX9) generated 201.10 million EUR in revenue last year, primarily from its Innovative Therapeutics segment. The United States was the largest contributor to this revenue, accounting for 201.10 million EUR. This represents an increase from the previous year's revenue of 154.73 million EUR.
Akebia Therapeutics (AKBA) Q2 2024 earnings summary
Akebia Therapeutics (AKBA) reported a narrowed net loss in Q2 2024, driven by lower R&D and cost of goods sold, with total revenue at $43.6M. The company’s new drug, Vafseo, received FDA approval and is set for a U.S. launch in January 2025, while Auryxia remains the main revenue driver but faces loss of U.S. exclusivity in March 2025. Akebia projects sufficient liquidity for at least two years and plans to expand Vafseo's market presence.
Short Interest in Akebia Therapeutics, Inc. (NASDAQ:AKBA) Declines By 34.3%
Short interest in Akebia Therapeutics (NASDAQ:AKBA) significantly decreased by 34.3% in June, totaling 19.2 million shares. This represents about 7.5% of the company's shares sold short, with a days-to-cover ratio of 2.7. The article also notes an insider stock sale by CFO Erik Ostrowski and mentions mixed analyst sentiment with a "Hold" consensus rating.
Akebia Therapeutics (NASDAQ:AKBA) Shares Pass Above Fifty Day Moving Average - Here's What Happened
Akebia Therapeutics (NASDAQ:AKBA) shares have surpassed their 50-day moving average, trading as high as $1.41 after crossing the $1.11 mark with significant trading volume. Analyst sentiment is mixed, with some downgrades and reiterations of bullish views, leading to a consensus "Hold" rating and an average price target of $4.67. The company recently missed EPS expectations but beat
Lobbying Update: $60,000 of AKEBIA THERAPEUTICS INC. lobbying was just disclosed
Akebia Therapeutics Inc. (AKBA) recently disclosed $60,000 in lobbying expenditures for Q2 2026, primarily focused on influencing payment policies for innovative drugs within Medicare's ESRD PPS. The article also provides a detailed overview of AKBA's insider trading activity, revealing significantly more sales than purchases over the past six months, along with notable hedge fund movements and recent analyst ratings and price targets for the stock.
ETFs Investing in Akebia Therapeutics, Inc. Stocks
This article lists various ETFs that hold Akebia Therapeutics, Inc. (AX9) stocks, providing details such as market value, weight, issuer, management style, expense ratio, and total return. It highlights how these funds can make investing in stocks more accessible and offer diversified opportunities. The ETFs listed include those focused on small-cap, micro-cap, health care, and biotechnology sectors.
Akebia Therapeutics (AKBA) Q2 2024 earnings summary
Akebia Therapeutics' Q2 2024 earnings report highlights a narrowed net loss and preparation for the U.S. launch of Vafseo in January 2025. The company regained full U.S. rights to Vafseo, enhancing its operational strategy, while Auryxia remains the main revenue source despite impending loss of exclusivity. Akebia projects sufficient liquidity for at least two years and plans to expand Vafseo's market presence.
Akebia Therapeutics (AKBA) Jefferies Global Healthcare Conference 2026 Summary
Akebia Therapeutics (AKBA) presented at the Jefferies Global Healthcare Conference in 2026, focusing on the commercial performance of its kidney disease drugs, Vafseo and Auryxia, and its clinical development pipeline. Vafseo, their primary growth driver, showed significant increases in prescribing physicians and patients, with strong refill rates. The company also detailed its rare renal disease pipeline, including praliciguat and AKB-097, and discussed ongoing clinical studies for Vafseo.
Akebia Therapeutics (AKBA) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary
Akebia Therapeutics' summary from the Guggenheim Securities Biotech Summit 2026 highlights its focus on kidney disease with commercial products AURYXIA and VAFSEO, and an expanding pipeline for rare kidney conditions. The company is addressing initial VAFSEO usage challenges with improved dosing strategies and expects significant growth from ongoing clinical trials like VOCAL and VOICE, aiming to establish VAFSEO as a standard of care in the ESA market.
Zacks Research Upgrades Akebia Therapeutics (NASDAQ:AKBA) to Hold
Zacks Research has upgraded Akebia Therapeutics (NASDAQ:AKBA) from a "strong sell" to a "hold" rating, indicating a more neutral outlook for the stock. Despite a recent quarterly loss, the biopharmaceutical company reported revenues slightly above expectations, leading to a 4.4% increase in share price to $1.42 on Tuesday. The consensus among analysts from MarketBeat is currently a "Hold" with an average price target of $4.67, reflecting mixed opinions with some analysts maintaining "Buy" ratings and others downgrading to "Sell."
Akebia Therapeutics (AKBA) Wells Fargo 20th Annual Healthcare Conference 2025 summary
This article summarizes Akebia Therapeutics' presentation at the Wells Fargo 20th Annual Healthcare Conference 2025. The company highlighted its focus on kidney disease with commercial products Auryxia and Vafseo, the latter targeting a significant U.S. market and showing strong initial commercial traction. Akebia also emphasized its financial strength and Vafseo's clinical value in treating anemia for CKD patients on dialysis.
Akebia Therapeutics (AKBA) Proxy filing Summary
Akebia Therapeutics (AKBA) has released a proxy filing summary detailing the proposals for its virtual annual meeting on June 17, 2026. Key items include the election of three Class III directors, an amendment to increase authorized capital stock, an advisory vote on executive compensation, and the ratification of Ernst & Young LLP as the independent auditor. The board recommends voting in favor of all proposals, emphasizing the company's progress with Vafseo's market access, pipeline advancements, and strong financial outlook.
AKBA - Akebia Therapeutics Inc Options
This article provides comprehensive financial data and performance metrics for Akebia Therapeutics Inc. (AKBA), including its market capitalization, sales, earnings per share, and various valuation ratios. It also highlights institutional and insider ownership, profitability margins, and stock performance over different periods.
Akebia Therapeutics (AKBA) Wells Fargo 20th Annual Healthcare Conference 2025 summary
Akebia Therapeutics presented at the Wells Fargo 20th Annual Healthcare Conference in 2025, highlighting its focus on kidney disease with two commercial products: Auryxia and Vafseo. The company reported strong financial performance with $137 million in cash and projected profitability, driven by Vafseo's successful launch and market penetration in the dialysis anemia market. Vafseo generated $13.3 million in Q2 revenue, with expanding market access and positive clinical feedback.
